TPST's Business Model
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.tempesttx.com |
| CEO (Chief Executive Officer) | Stephen R. Brady |
| Number of Employees | |
| IPO date | November 12, 2012 |
TPST Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 7000 Shoreline Court |
| City | Brisbane |
| State | CA |
| Phone | 415 798 8589 |
| Zip Code | 94080 |
| Other Identifiers | |
| CIK | 0001544227 |
| ISIN | US87978U2078 |
| CUSIP | 87978U207 |
| Open | 2.73 |
| Previous Close | 2.72 |
| Volume | 83.64 Thou. |
| Average Volume | 131 Thou. |
| Day’s Range | 2.43 – 2.73 |
| 52 Week Range | 2.4-12.48 |
| MA (50) | 3.1677 |
| MA (200) | 7.14706 |
| Market Cap | 12.17 Mil. |
| Shares Out. | 4.93 Mil. |
| Earnings Date | Apr 01, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
